Arcoxia is a new COX-2 selective inhibitor from Merck
& Company used for the treatment of rheumatoid arthritis,
osteoarthritis, chronic low back pain, gout, and ankylosing
spondylitis. Arcoxia tablets contain an active ingredient
called Etoricoxib, which is a type of medicine known as a
non-steroidal anti-inflammatory drug (NSAID). NSAIDs work by
blocking the action of a substance in the body called
cyclo-oxygenase, which is involved in producing
prostaglandins, in response to injury or certain diseases.
These prostaglandins cause swelling, pain and inflammation.
Because NSAIDs block the production of these prostaglandins,
they are very much effective at relieving pain and
Cyclo-oxygenase does not only produce prostaglandins that
cause inflammation but also produces prostaglandins that
have useful roles in the body. There are two different types
of cyclo-oxygenase, COX-1 and COX-2. COX-2 is the form that
produces prostaglandins that cause inflammation. COX-1 does
not produce inflammatory prostaglandins, but produces others
that have useful effects, including some that are involved
in maintaining a healthy stomach and intestinal lining.
NSAIDs, block the action of both COX-1 and COX-2, and this
is why they can sometimes cause side effects such as stomach
irritation and peptic ulcers. Arcoxia belongs to a new
generation of NSAIDs that selectively block the action of
COX-2. This means that it stops the production of
inflammatory prostaglandins, without stopping the production
of prostaglandins that protect the intestine and the
stomach. Arcoxia therefore reduces pain and inflammation,
but is less likely than traditional NSAIDs to cause side
effects on the stomach and intestines.
Arcoxia has been launched in 48 countries worldwide in Latin
America, Europe and the Asia-Pacific region. Merck will
continue to work with regulatory agencies in the countries
where Arcoxia is approved, including the European Medicines
Agency which recently announced plans for the safety review
of the COX-2s, to assess whether changes to the prescribing
information for this class of drugs, including Arcoxia, are
warranted. Some of the Latest drugs for 2006
daevobet and xolaire.
Field Marked with asterisk (*) are